Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baclofen add-on for inpatient GHB detoxification
NL-OMON59194Phase 2Withdrawn
- Sponsor
- Radboud University Medical Center
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of baclofen in gamma-hydroxybutyrate use disorder (GHBUD), sponsored by Radboud University Medical Center. Primary endpoint: Pharmaceutical GHB dosage at the end of the titration phase. Planned start Aug 2023; status: withdrawn.
02
Drugs
baclofen
03
Conditions
gamma-hydroxybutyrate use disorder (GHBUD)
Beyond the preview
Go deeper on NL-OMON59194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59194.